Overview

• A 2025 review identified 182 Alzheimer’s clinical trials testing 138 candidate drugs, marking an 11% increase from last year.
• One-third of studies repurpose existing medications originally approved for conditions such as diabetes, multiple sclerosis and high cholesterol.
• Four late-stage trials focus on preventing Alzheimer’s onset rather than solely treating its symptoms.
• Semaglutide, the active ingredient in Ozempic and Wegovy, is under investigation for its potential to slow dementia progression.
• NICE is assessing the cost-effectiveness of lecanemab and donanemab for NHS use, with a decision expected this summer.